A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension
Hypertension
About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria: Male or non-pregnant female patients aged 18-70 years. Patients had hypertension with sitting systolic blood pressure 140-180 mmHg, or diastolic blood pressure 90-110 mmHg. Patients must give written informed consent to participate in this study. Exclusion Criteria: Women who are pregnant or nursing. Patients have the evidence of secondary or malignant hypertension, history of severe heart disease, cerebrovascular accident within one year, or myocardial infarction within six months. Patients receiving more than one anti-hypertensive agents or one antihypertensive agent with maximal recommended dosage before entrance into the trial. Patients with uncontrolled diabetes mellitus. Patients had known hypersensitivity or contraindication to nifedipine, other calcium channel blockers or other beta-adrenergic antagonists. Patients have the evidences of hepatic dysfunction (AST, ALT> 3 times upper limit of normal value), renal dysfunction (serum creatinine concentration>1.5 mg/dl), pulmonary dysfunction, mental disorders or other concurrent severe disease. As to the study of flow-mediated dilatation and oxidative stress, patients with diabetes mellitus, dyslipidemia, body mass index >27, and smokers will be excluded.
Sites / Locations
- Cardiovascular Division, Department of Internal Medicine, National Taiwan University Hospital